No adverse events were observed in clozapine-treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan.

Aim: As an emergency measure during the coronavirus disease pandemic, the monitoring interval for clozapine use was temporarily extended beyond the regulatory requirement in Japan, which is the safest monitoring interval worldwide. In this study, we aimed to explore the effect of this measure on patients undergoing clozapine treatment.

Methods: This retrospective chart review study included patients with treatment-resistant schizophrenia (TRS) who were undergoing clozapine treatment at four psychiatric institutions in Japan.

Hyperactivity and comorbidity in Japanese children with attention-deficit/hyperactivity disorder.

No previous study about comorbidity of attention-deficit/hyperactivity disorder (ADHD) in Japan have carried out both a comprehensive investigation using a structured interview and a comparison between ADHD subtypes. The aim of the present study was to clarify the relationship between hyperactivity and disruptive behavior disorder (DBD) in ADHD by comparing a hyperactivity group (HG) with a non-hyperactivity group (non-HG). After diagnosis was carried out by strict exclusion, the 41 ADHD subjects (6-14 years old; IQ, 70-121) diagnosed according to DSM-IV were divided into HG (n = 24) and non-HG (n = 17), and compared for comorbidities and psychopathologies.